Gutzler, C.; Höhne, K.; Bani, D.; Kayser, G.; Fähndrich, S.; Ambros, M.; Hug, M.J.; Rieg, S.; Falcone, V.; Müller-Quernheim, J.;
et al. Vasoactive Intestinal Peptide (VIP) in COVID-19 Therapy—Shedding of ACE2 and TMPRSS2 via ADAM10. Int. J. Mol. Sci. 2025, 26, 2666.
https://doi.org/10.3390/ijms26062666
AMA Style
Gutzler C, Höhne K, Bani D, Kayser G, Fähndrich S, Ambros M, Hug MJ, Rieg S, Falcone V, Müller-Quernheim J,
et al. Vasoactive Intestinal Peptide (VIP) in COVID-19 Therapy—Shedding of ACE2 and TMPRSS2 via ADAM10. International Journal of Molecular Sciences. 2025; 26(6):2666.
https://doi.org/10.3390/ijms26062666
Chicago/Turabian Style
Gutzler, Charlotte, Kerstin Höhne, Daniele Bani, Gian Kayser, Sebastian Fähndrich, Michael Ambros, Martin J. Hug, Siegbert Rieg, Valeria Falcone, Joachim Müller-Quernheim,
and et al. 2025. "Vasoactive Intestinal Peptide (VIP) in COVID-19 Therapy—Shedding of ACE2 and TMPRSS2 via ADAM10" International Journal of Molecular Sciences 26, no. 6: 2666.
https://doi.org/10.3390/ijms26062666
APA Style
Gutzler, C., Höhne, K., Bani, D., Kayser, G., Fähndrich, S., Ambros, M., Hug, M. J., Rieg, S., Falcone, V., Müller-Quernheim, J., Zissel, G., & Frye, B. C.
(2025). Vasoactive Intestinal Peptide (VIP) in COVID-19 Therapy—Shedding of ACE2 and TMPRSS2 via ADAM10. International Journal of Molecular Sciences, 26(6), 2666.
https://doi.org/10.3390/ijms26062666
